The mechanism of CD4 ؉ T-cell depletion in human immunodeficiency virus type 1 (HIV-1)-infected individuals remains unknown, although mounting evidence suggests that direct viral cytopathicity contributes to this loss. The HIV-1 Vpr accessory protein causes cell death and arrests cells in the G 2 /M phase; however, the molecular mechanism underlying these properties is not clear. Mutation of hydrophobic residues on the surface of its third alpha-helix disrupted Vpr toxicity, G 2 /M arrest induction, nuclear localization, and self-association, implicating this region in multiple Vpr functions. Cytopathicity by virion-delivered mutant Vpr protein correlated with G 2 /M arrest induction but not nuclear localization or self-association. However, infection with whole virus encoding these Vpr mutants did not abrogate HIV-1-induced cell killing. Rather, mutant Vpr proteins that are impaired for G 2 /M block still prevented infected cell proliferation, and this property correlated with the death of infected cells. Chemical agents that inhibit infected cells from entering G 2 /M also did not reduce HIV-1 cytopathicity. Combined, these data implicate Vpr in HIV-1 killing through a mechanism involving inhibiting cell division but not necessarily in G 2 /M. Thus, the hydrophobic region of the third alpha-helix of Vpr is crucial for mediating G 2 /M arrest, nuclear localization, and self-association but dispensable for HIV-1 cytopathicity due to residual cell proliferation blockade mediated by a separate region of the protein.
Human immunodeficiency virus type 1 (HIV-1) infection is characterized by a progressive and inexorable decline in circulating CD4
ϩ T cells, resulting in susceptibility to the lethal opportunistic infections seen in AIDS. Kinetic modeling and quantitative image analyses support a model in which peripheral blood CD4 ϩ T cells turn over rapidly in a cycle of infection, elimination, and replenishment in HIV-1-infected individuals (21, 27, 70) . Recent evidence suggests that the mucosal tissue harboring naive and memory T cells suffers a 30 to 60% loss of CD4 ϩ T cells infected with the virus within 2 weeks during the early acute stages of simian immunodeficiency virus (SIV) and HIV-1 infection (7, 38) . Several direct and indirect causes have been proposed to account for this loss, including effects on both T-cell destruction and production (22, 39) . Although bystander death of uninfected cells, as well as cellmediated cytotoxicity against HIV-1-infected cells, may contribute to T-cell depletion, viral replication within CD4 ϩ T lymphocytes causes direct viral cytopathicity in these cells by a necrotic form of cell death (5, 8, 34) . Therefore, elucidating the mechanism of direct HIV-1 cytopathicity may help to clarify, and ultimately uncover means to prevent, the decline in CD4 ϩ T cells in infected individuals.
The HIV-1 accessory protein viral protein R (Vpr) is an important determinant of viral cytopathicity and can independently kill cells in the absence of viral infection (45, 55, 60) .
Mutation of the vpr homologues, vpr and vpx, results in severe attenuation of SIV replication in rhesus monkeys, indicating that Vpr is essential for replication and pathogenesis in vivo (18) . Moreover, Vpr is highly conserved among primate lentiviruses with significant sequence and functional homology across primate lentiviral groups (66) . Vpr also induces remarkable cell cycle arrest in the G 2 /M phase characterized by tetraploid DNA content (23, 29, 52, 53) . Several other properties have been described for Vpr, including nuclear translocation of the viral preintegration complex (24) , enhancement of transcriptional activity of the HIV-1 LTR promoter by severalfold (1, 15, 19, 20, 68) , disruption of nuclear membrane integrity (13) , and induction of centrosomal abnormalities (10, 41, 69) and apoptosis (26, 33, 57, 65, 72) . It is thought that many, if not all, of these effects may be due to the propensity of Vpr to localize to the nucleus.
The ability to cause cell cycle blockade is conserved among Vpr proteins from a wide variety of HIV and SIV isolates (62) . Controversy surrounds the role of cell cycle arrest in Vprinduced death. Compounds that alleviate Vpr G 2 /M arrest, such as caffeine, can reduce apoptosis induced by Vpr (75) , while analysis of amino acid substitutions in Vpr showed a correlation between cell cycle arrest and a reduction in viable cells (60, 71) . However, other evidence suggests that cell cycle blockade and cytopathicity are independent functions. For example, Vpr death was intact when the G 2 /M arrest was abrogated by the drug pentoxifylline (60) , and some Vpr point mutants with cell cycle arrest activity fail to induce apoptosis (11, 47) . Still other experiments indicate that the cytostatic effect of Vpr serves to prevent cell death and, by some accounts, protects against apoptotic stimuli (4, 12) . It has been difficult to reconcile these disparate results. Vpr toxicity may depend on protein abundance within the cell, since low-level Vpr expression is generally associated with antiapoptotic ac-tivity (12, 16) . A more thorough examination of the significance of Vpr G 2 /M blockade for cytopathicity in T cells is warranted. In addition, it remains to be determined whether accumulation in G 2 /M phase is required for HIV-1-mediated cell death.
Recent determination of the structure for full-length Vpr by nuclear magnetic resonance (NMR) could offer new insights into Vpr function, including its cytopathic effects (43) . Vpr forms three well-defined alpha-helices with two separate hydrophobic patches exposed on the outer surface of the first and third helices. A series of hydrophobic residues orientated toward the aqueous cytoplasmic environment would be expected to physically destabilize a protein, unless another molecule binds these regions. Thus, the exposed hydrophobic patches likely mediate Vpr interaction with itself and/or other proteins. Evidence for Vpr self-association has come from several different in vitro systems, including dimeric Vpr by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (48) , multimeric complexes of recombinant Vpr by gel filtration and dynamic light scatter analysis (25, 73) , and homodimerization of Vpr C-terminal fragments (amino acids 52 to 96) by circular dichroism and yeast two-hybrid analysis (58) . Together, these data indicate that Vpr likely self-associates within living cells, but the significance of Vpr self-association and its regulation in live cells remain unknown. Thus, a better understanding of the relationship between Vpr dimerization and cell cycle blockade and cytotoxicity could be useful in the development of antiretroviral strategies targeting Vpr function.
We used the structural information to design Vpr mutants that test the involvement of the third-helix superficial hydrophobic residues in Vpr activity and assess the interdependence of the known functions of Vpr. By targeting residues with an outward-facing orientation we aimed to minimize the likelihood of compromising the predicted global conformation of Vpr, such as the folding of the helices around the hydrophobic core. Alteration of the hydrophobic residues impaired the cell cycle arrest and cytotoxic functions of the protein. In addition, nuclear localization and Vpr self-association were markedly reduced upon mutation of this region. Strikingly, the active mutant I70S, which retained the ability to block cells in G 2 /M and cause cell death, did not localize to the nucleus or oligomerize normally, suggesting these Vpr functions are executed from the cytoplasm by monomeric protein. Unexpectedly, infection with HIV-1 virus encoding Vpr mutants with attenuated G 2 /M arrest ability was as lethal as WT virus, suggesting blockade in G 2 /M is not required for viral cytopathicity. Moreover, HIV-1 cytopathicity proceeded unabated in cells chemically arrested in the G 1 phase. These data suggest that Vpr causes infected cell death independent of the third alphahelix hydrophobic region and G 2 /M cell cycle block and that a previously unappreciated inhibition of proliferation, irrespective of any particular cell cycle stage, may be a key component of HIV-1 cytopathicity.
MATERIALS AND METHODS
Cell lines. Jurkat and SupT1 T cells were maintained in RPMI 1640 (Cambrex, East Rutherford, NJ) supplemented with 10% fetal calf serum, 100 U of penicillin-streptomycin/ml, 2.4 mM L-glutamine, and 50 M ␤-mercaptoethanol. All Jurkat experiments were conducted by using a CD4
hi Jurkat subclone, Jurkat 1.9, generated by single-cell sorting of a low CD4-expressing parental JAK3 cell line (5) . 293T cells were maintained in Dulbecco modified Eagle medium supplemented as described above. Drugs added to cultures included the following: 3 mM caffeine (Sigma-Aldrich), indirubin-3Ј-monoxime (A.G. Scientific, Inc., San Diego, CA), and piceatannol (Calbiochem, San Diego, CA).
Transfection. Transient transfection of Jurkat cells with Vpr expression constructs was performed by electroporation using an Electro Cell Manipulator (BTX, Holliston, MA) apparatus. A total of 4 ϫ 10 6 cells resuspended in 0.4 ml of growth medium and 10 to 15 g of DNA were electroporated in a 4-mm gap cuvette (Bio-Rad Laboratories, Hercules, CA) at 260 V and 1,060 F, followed by recovery in growth medium for 2 to 4 days. Transfection efficiency was routinely between 60 and 80% as determined by flow cytometric analysis of green fluorescent protein (GFP)-expressing cells 48 h posttransfection. Typically, pEGFP-N1 (Clontech, Mountain View, CA) was cotransfected with other expression plasmids at a ratio of 1:3.3 (e.g., 3 g of pEGFP-N1 with 10 g of pCDNA3-hVpr) as a marker of transfected cells. Vpr expressed by transient transfection off of a plasmid is referred to as Vpr t .
HIV virus stock and infections. HIV viral plasmids were obtained from the National Institutes of Health AIDS Research and Reference Reagent Repository unless otherwise indicated. HIV-1 viral stocks of NL4-3 n-GFP (pNLnEGFPKp; a gift from H. Akari [17] ) were prepared from cell-free supernatant from 293T cells transfected with plasmid by using ExGen (Fermentas, Hanover, MD) according to the manufacturer's recommendations and as described previously (5) . Briefly, all infections were conducted with env mutant derivatives of NL4-3 n-GFP (NL4-3 e-n-GFP ) pseudotyped with vesicular stomatitis virus G protein (VSV-G). Virus titers were assessed by functional multiplicity of infection (MOI) determination based on the Poisson distribution, in which the predicted frequency of 63.2% infected cells is expected after inoculation with an MOI equal to 1 in a single-round infection. Additional viral strains included a Vif mutant derivative of NL4-3 e-n-GFP , NL4-3 e-n-GFPf- (55) , and Vpr mutant derivatives of NL4-3 f-including deleted Vpr (NL4-3 f-r-, with an amino acid deletion from 22 to 86), and substitution mutants L67E, I70S, L74E, and R80A. Viral stocks of NL-EGFP (no HIV genes expressed) (42) were generated by cotransfection with the encapsidation mutant HIV-1 strain, CMV⌬R8.2⌬Vpr (44) . Virion Vpr (Vpr v ) was delivered to Jurkat cells by using a reverse transcriptase inactive mutant (D186N, RT-; a gift from E. Freed, National Cancer Institute, National Institutes of Health) derivative of NL4-3. To package mutant Vpr into virions, the coding sequence for Vpr was deleted (amino acids 22 to 86; data not shown) from RT-NL4-3 e-n-GFP , and this construct was cotransfected with a mutant Vpr expression plasmid. RT-viral stocks were normalized by delivery of HIV-1 p24 capsid protein to target cells by Western blotting. Typically, Jurkat T cells were inoculated at an MOI between 2 and 5 in 12-well (8 ϫ 10 5 cells/well) or 24-well (4 ϫ 10 5 cells/well) plates in the presence of Polybrene (5 g/ml; Sigma-Aldrich). Virus was adsorbed for 30 min at 37°C in 5% CO 2 , followed by centrifugation for 30 min at 800 ϫ g. Cultures were maintained at 5 ϫ 10 5 to 10 ϫ 10 5 cells/ml. Assays for viral production, cell viability, and cell cycle. HIV-1 cytopathicity was assessed by flow cytometric forward and side light scatter or forward scatter and propidium iodide (PI; Sigma-Aldrich) profiles of at least 10,000 live cells daily throughout the course of infection (FACScalibur; Becton Dickinson, Franklin Lakes, NJ). All fluorescence-activated cell sorting (FACS) data analysis was performed by using FlowJo software (Tree Star, Inc., Ashland, OR). Simultaneously, these samples were measured for HIV-1 provirus expression by either staining with anti-mouse HSA (CD24a; BD Pharmingen) or by GFP fluorescence. Infected viable cell number counts were measured by collection for a constant period of time per sample. To measure DNA content, cells were fixed in 1% paraformaldehyde (in phosphate-buffered saline [PBS]) for 10 min, washed once in PBS, resuspended in 70% ethanol with gentle mixing, incubated at Ϫ20°C for 30 min or overnight, washed in PBS, and resuspended in 200 l of DNA staining solution (5 g of PI/ml, 50 g of RNase/ml, and 0.45 mg of sodium citrate/ml in PBS) for 30 min at 25°C. Stained cells were processed on a FACScalibur or FACScan (Becton Dickinson) using the doublet discriminator module. Bromodeoxyuridine (BrdU) staining was performed by using the BD Pharmingen BrdU flow kit according to the manufacturer's instructions. Briefly, cells were pulsed for 60 min with 5 mM BrdU (Sigma-Aldrich), fixed with BD Cytofix/Cytoperm buffer, treated with 300 g of DNase/ml, and stained with anti-BrdU conjugated with Alexa Fluor 647 (Molecular Probes, Invitrogen), followed by DNA labeling with 7-amino-actinomycin D (7-AAD). BrdU-stained cells were processed on an LSR II (Becton Dickinson), and doublets were excluded by using a linear 7-AAD height-versus-area gate for analysis.
Expression plasmids. The HIV-1 NL4-3 vpr sequence was subcloned using the HindIII and BamHI restriction sites into pECFP-C1 and pEYFP-C1 (Clontech) for fluorescence resonance energy transfer (FRET) analysis. vpr was placed C terminal to the fluorophore because tests of an N-terminal position showed this inactivated Vpr cell cycle arrest function and FRET-detectable self-association. . vpr point mutations and deletions were generated by using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol using either PfuTurbo or PfuUltra polymerase (Stratagene). FRET. 293T human embryonic kidney cells were transiently transfected using ExGen (Fermentas) according to the manufacturer's instructions. pECFP-C1 and pEYFP-C1 plasmids (Clontech) were transfected alone, as a CFP-YFP fusion protein, or as fusion proteins with wild-type (WT) or mutant Vpr. The CFP and YFP plasmids were transfected at a 1:1 ratio, and cells were harvested 24 to 48 h posttransfection. Detection of FRET by flow cytometry was performed as described by Siegel et al. (59) , and all analyses were performed on CFP and YFP double-positive cells.
Immunofluorescence imaging. Jurkat cells were washed once in PBS and fixed in 4% paraformaldehyde for 30 min at 4°C. A total of 2 ϫ 10 5 cells in 0.2 ml were cytospun onto glass slides (Electron Microscopy Sciences, Hatfield, PA) and permeabilized for 5 min with 0.05% Triton X-100 (Sigma-Aldrich) in PBS, followed by three washes with PBS. Mounted cells were then saturated with 10% fetal calf serum in PBS for 30 min at 25°C, washed twice in PBS, incubated in primary antibody against Vpr (K. Strebel, NIAID) at a 1:200 dilution in 0.5% bovine serum albumin-PBS, washed three times in PBS, incubated in Texas red-conjugated goat anti-rabbit antibody (Jackson Immunoresearch, West Grove, PA) diluted 1:200, and washed again. All antibody stainings were conducted at 25°C for 45 min. Nuclei were stained with Hoechst 33342 (40 ng/ml; Invitrogen Molecular Probes, Carlsbad, CA) at 1:10,000 in PBS for 5 min, followed by three washes with PBS. Slides were mounted in 5 l of Fluoromount-G (Southern Biotech, Birmingham, AL) with a glass coverslip (Fisher Scientific, Pittsburgh, PA). Cells were imaged by confocal microscopy on a Leica TCS-NT/SP1.
Immunoblotting. For standard Western blotting, whole-cell protein extracts were prepared by lysis for 30 min on ice in modified Laemmli buffer (60 mM Tris [pH 6.8], 10% glycerol, and 2% sodium dodecyl sulfate [SDS]), followed by DNase (Benzonase nuclease; Novagen, San Diego, CA) treatment for 30 min. Complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) was included in all lysis buffers. Protein concentration in lysates was estimated by bicinchoninic acid assay (Pierce, Rockford, IL). Equal protein mass was electrophoresed on a 4 to 20% Tris-glycine-SDS gel (Invitrogen Novex) and blotted onto nitrocellulose using a semidry transfer apparatus (Bio-Rad).
Cytoplasmic and nuclear separation extracts were prepared by cell lysis in electrophoretic mobility shift assay buffers as previously described (63), with modifications. Briefly, 5 ϫ 10 6 cells were gently lysed in buffer A for 5 min and centrifuged to collect the cytoplasmic supernatant. Pelleted nuclei were lysed in buffer C for 10 min on ice, and the nucleoplasm was harvested after centrifugation at 12,000 ϫ g for 10 min. Lysates were separated by SDS-polyacrylamide gel electrophoresis as described above.
Blots were blocked with 2.5% nonfat dry milk in 0.1% PBS-Tween 20 (PBS-T), probed with primary antibody, followed by horseradish peroxidase-conjugated secondary antibody diluted 1:10,000, with three 5-min washes in PBS-T after each 30-min incubation. All antibody probes were performed in 2.5% nonfat dry milk and 0.1% PBS-T. Blots were stripped with Re-Blot Plus Mild (Chemicon International, Temecula, CA) for 20 min and blocked again before reprobing. Bands were imaged with enhanced chemiluminescent substrate (Amersham, Piscataway, NJ) or SuperSignal West Dura (Pierce). The antibodies used with corresponding catalog numbers were as follows: ␤-actin (A5441; Sigma-Aldrich), PARP (P76420; BD Transduction Laboratories), and HIV-1 Vpr (K. Strebel).
RESULTS
Glutamic acid substitutions in the exposed hydrophobic residues of Vpr helix three impair G 2 /M arrest function. NMR structure revealed that full-length Vpr consists of at least three ␣-helices that fold around a hydrophobic core, with flexible N and C termini and a possible fourth helix in the C terminus (43) . The third alpha-helix has been shown to be important for Vpr cell cycle arrest function (14, 36) . We hypothesized that the hydrophobic residues in helix three-I63, L67, I70, and I74-oriented to the outside of the Vpr protein (Fig. 1A ) may serve as a protein-protein binding region critical for Vpr interaction with either a cellular protein or itself in order to mediate its functions. We therefore studied the requirement for the third helix hydrophobic patch in Vpr cell cycle arrest, cytotoxicity, and self-association after substituting each of these residues with alanine, serine, or glutamic acid. Delivery of WT or mutant Vpr protein via HIV-1 virions (Vpr v ) using a reverse transcriptase mutant derivative of NL4-3 e-n-GFP ( Fig.  1B and data not shown) showed that Vpr G 2 /M blockade was dramatically attenuated when these residues were changed to glutamic acid (Fig. 1C, left) . The ratio of cells in G 2 /M to G 1 (R) induced by WT Vpr v was 6.2 (medium dose), whereas substitution of I63, L67, or I74 with glutamic acid reduced the blockade ratio to 2.1, 1.0, and 1.0, respectively. By comparison, complete deletion of Vpr gave a ratio of 0.2. Thus, the L67E and I74E substitutions had the greatest effect. I70E was not efficiently delivered by the virion (data not shown). Expression and stability of the mutants were verified by Western blot, which showed all Vpr mutants present at equal levels in the target Jurkat cells, indicating that each had been appropriately packaged into the virion and delivered (Fig. 1C, right) . The amount of virion-delivered viral capsid protein was also comparable, indicating that a similar amount of virus was applied to the cells. Substitution of I70 with serine did not impair G 2 /M blockade activity (Fig. 1C , R ϭ 5.7) but did disrupt other Vpr properties as described below. The R80A mutant, which fails to be phosphorylated at S79 and completely lacks G 2 /M blockade function (74), did not cause any accumulation in G 2 /M (R ϭ 0.3), as expected. Only mild effects were noted with serine or alanine replacements of individual hydrophobic residues (data not shown), suggesting that the negative charge imparted by glutamic acid disrupts Vpr activity. Substitution of multiple residues to alanine or serine resulted in poor Vpr expression, presumably due to compromised protein stability (data not shown).
We also evaluated these mutants by transfection directly in Jurkat cells to characterize endogenously expressed protein (Vpr t ) (Fig. 1D) . These experiments yielded similar results, and the G 2 /M block by I70S was actually enhanced relative to WT Vpr, suggesting that the isoleucine at this site may function as a negative regulator of cell cycle arrest activity. The cell cycle arrest activity of the Vpr mutants after virion delivery (three experiments) and transfection (one experiment) is summarized in Fig. 2A . Interestingly, cell cycle arrest was not as potent when the protein was endogenously expressed in T cells by transfection compared to delivery by a virion, despite significantly greater Vpr abundance upon transfection (data not shown). In summary, mutation of three of the exposed hydrophobic residues of the third helix to a negatively charged residue interfered with Vpr-induced G 2 /M arrest.
Vpr G 2 /M arrest activity correlates with induction of cell death. To determine whether G 2 /M blockade correlated with Vpr cytopathicity, we further tested the mutants for their ability to kill Jurkat T cells upon virion delivery. Vpr v -induced cell death was proportional to the extent of G 2 /M blockade caused by each of the mutants, with R80A, L67E, and I74E showing a large reduction in cytopathicity ( Fig. 2B ; the corresponding cell cycle data are shown in Fig. 2A, series b) . The 25 to 40% decrease in cell viability caused by WT Vpr v is consistent with other reports of virion-associated Vpr killing (61) . I63E, which exhibited an intermediate G 2 /M arrest phenotype, caused minimal death, whereas I70S, which induced a strong G 2 /M arrest, induced the most death of any of the mutants. Thus, G 2 /M blocking activity of Vpr mutants correlated directly with the propensity to kill T cells.
Strong nuclear localization is neither required nor sufficient for Vpr G 2 /M arrest. Since G 2 /M blockade preceded cell death, we explored how Vpr accomplishes cell cycle arrest to gain potential insight into the death mechanism. Vpr nuclear localization was evaluated in the panel of mutants using indirect immunofluorescence. WT Vpr and the cell cycle arrest dead mutant, R80A, showed a predominant nuclear localization with distinct exclusion from nucleoli in transfected Jurkat cells (Fig. 3A) (14, 35) . In contrast, the strong G 2 /M blocking mutant, I70S, as well as the other helix three mutants were predominantly cytoplasmic with most cells exhibiting a staining pattern surrounding the nucleus (Fig. 3A and B) . Thus, mutations in the exposed hydrophobic residues impaired the nuclear localization of Vpr. Fractionation of Jurkat cells into cytoplasmic and nuclear extracts and immunoblotting also revealed that I70S mutation reduced nuclear expression of Vpr (lane 2 compared to lanes 1 and 3, Fig. 3C ). Together, these data provide strong evidence for a cytoplasmic mode of Vprinduced cell cycle arrest, although it is also possible that a small amount of nuclear Vpr is sufficient to mediate the G 2 /M block. Moreover, nuclear localization is not sufficient for cell cycle arrest given the robust nuclear presence of R80A. Vpr oligomerization can be detected in real time, but multimers are not sufficient or required for G 2 /M arrest. We next investigated whether Vpr-Vpr binding occurs in live human cells using flow cytometric FRET to detect proximity at 100 Å or less (59) . Vpr-fluorophore fusion proteins were transfected into 293T cells, and significant FRET was detected between WT Vpr molecules (Fig. 4 , change in mean fluorescence intensity [⌬MFI] ϭ 9.7 relative to the CFP-Vpr and YFP cotransfected control), indicating that Vpr binds to itself in living cells. Hydrophobic patch mutants, I63E and I70S, however, both failed to self-associate (⌬MFI Ͻ 1.0). Since I70S causes G 2 /M block, Vpr self-binding is apparently not required for cell cycle arrest activity. In fact, self-association may negatively regulate G 2 /M blockade, since transfected I70S often induced a stronger G 2 /M block than WT Vpr (Fig. 2A, Vpr t ) . A lack of such regulation for the I63E mutant could also explain why it is not more severely attenuated in cell cycle blockade and killing. Conversely, basic residue mutants in the C-terminal loop that attenuate cell cycle arrest, R80A and R87/88A, showed increased self-association (⌬MFI ϭ 14.3 and 26.9, respectively, but 100 and 50% reduction in cell cycle block, respectively, Fig. 2A and data not shown) . A Vpr deletion mutant lacking residues 22 to 87 generated little FRET signal (⌬MFI ϭ 1.8), confirming that the Vpr signal is specific (Fig.  4) . In summary, the hydrophobic residues in the third helix are important for Vpr self-association. However, self-association of Vpr is not required for cell cycle arrest and may even reduce it. For the mutants studied, nuclear localization did correlate with self-association, suggesting that oligomerized Vpr may expedite or facilitate nuclear entry.
Mutant Vpr retains cytopathic activity during HIV-1 infection. To examine further whether cell cycle arrest correlates with cytopathicity in T cells, we tested the third-helix hydrophobic patch mutants in the context of an HIV-1 infection. Because the HIV-1 accessory protein, Vif, also has G 2 /M blocking activity and induces cytopathicity (55), we tested the mutants in an NL4-3 strain lacking Vif (NL4-3 e-n-GFPf-). Viral cytopathicity is markedly reduced when both Vif and Vpr are removed from NL4-3, although some death is still apparent when an MOI of 2 is used to achieve Ն90% infection (Fig. 5A ) (55) . Unexpectedly, we found that Vpr mutants with severe attenuation in G 2 /M blockade, L67E and I74E, were as lethal as WT Vpr (40% viable 100 h postinfection; Fig. 5A ) when the MOI was matched to achieve the same percentage of infected cells (Fig. 5B) . The mutants were still impaired for G 2 /M arrest activity, since infected cells showed a decrease in G 2 /M accumulation relative to WT Vpr (Fig. 5C) . The defect in G 2 /M blockade was similar to that seen upon Vpr v treatment or hVpr transfection of the mutants (Fig. 1C and D) . However, cultures infected with the mutant Vpr virus strains failed to proliferate (Fig. 5D) , even though the G 2 /M block was reduced. Thus, L67E and I74E Vpr mutants caused less G 2 /M accumulation in an HIV-1 infection but still inhibited cell proliferation as well as WT Vpr. This apparently occurs through a partial G 1 block, since approximately half of the culture contained 2N DNA content (Fig. 5C) . A small population of WT Vpr-arrested cells also stops in G 1 with diploid DNA content (Fig. 5C, for ple), which is consistent with the G 1 block Vpr causes in rodent cells (3) . To confirm the G 1 cell cycle arrest in these mutants, we pulsed infected cultures with BrdU to measure DNA synthesis. Although 42% of mock-infected and 30% of Vpr-deficient NL4-3 e-n-GFPf--infected cells incorporated BrdU, only 5.2 and 12% of the L67E and I74E mutant-infected cells, respectively, were BrdU positive (Fig. 5E) . The low level of BrdU incorporation among these mutants was similar to that caused by WT Vpr (8.6%). Thus, G 1 exit is markedly reduced by L67E and I74E Vpr.
To test HIV-1 cytopathicity with a Vpr mutant even more deficient in G 2 /M arrest activity, we performed the same comparison using NL4-3 e-n-GFPf-encoding R80A Vpr. Matching infections based on the percentage of infected (GFP ϩ ) cells (Fig. 5B) , R80A was also as lethal as WT Vpr, killing approximately half of the culture by 100 h postinfection (Fig. 5A) . Cell cycle analysis confirmed that infection with R80A Vpr virus (Vif-) failed to block cells in G 2 /M (Fig. 5C ). However, these cells did not proliferate as rapidly as NL4-3 e-n-GFPf-r--infected cultures by day 2 (before the onset of viral cytopathic effects; Fig. 5D ), and they had a similar defect for BrdU incorporation as cells expressing WT Vpr (11 and 8.6%, respectively, compared to 30% with deleted Vpr [Fig. 5E]) . Hence, the R80A mutant demonstrates that G 2 /M blockade is not required for Vpr to facilitate HIV-1 cell killing, supporting our observations of the hydrophobic patch mutants L67E and I74E. Rather, inhibition of cell proliferation, by blocking the cell cycle predominantly at the G 1 phase with some (49, 56) . As expected, HIV-infected cells treated with caffeine failed to accumulate in G 2 /M (Fig. 6A) . We found that shifting the cell cycle status did not, however, protect the cells from viral cytopathic effects, since caffeine-treated infected cells died with similar kinetics and magnitude as untreated cells (Fig. 6B) . Interpretation of these results was complicated by two factors, however. First, caffeine, like many of the compounds that perturb cell cycle regulation, exhibited moderate intrinsic toxicity on Jurkat T cells (Fig. 6B) . Second, caffeine interfered with viral infection at early time points since the percentage of GFP ϩ cells was reduced at 12 and 38 h postinfection (Fig. 6B, right) , although complete infection of the culture was obtained by day 3. Overall, however, infected cell death proceeded unabated, and only a minority of the cells was in G 2 /M. Thus, accumulation in G 2 /M is apparently unnecessary for viral cell killing.
Given the complexity of interpreting viral cytopathicity curves in the presence of a slightly toxic drug such as caffeine, we evaluated less toxic alternatives. Indirubin, a potent cyclindependent kinase (Cdk) inhibitor that arrests Jurkat cells in G 1 (28) , and piceatannol, a tyrosine kinase inhibitor that prevents Stat3 activation and centrosome duplication (40, 64) , were tested in HIV-infected Jurkat cells. We observed that treatment of Jurkat cells with these compounds alone did not significantly alter the DNA content profile in uninfected cells (Fig. 6C, left column) , but HIV-1 infection-induced G 2 /M accumulation was dramatically reduced (middle column). This was due primarily to blocking cell division at the G 1 phase, since both piceatannol and indirubin prevented cell proliferation while DNA analysis showed cells to be mostly in G 1 ( Fig.  6C and D, lower right panel) . Unlike caffeine, indirubin and piceatannol were not toxic at concentrations that effectively prevented the G 2 /M blockade (10 M), although mild toxicity was observed at higher concentrations of piceatannol (30 M, Fig. 6D ). As with caffeine, HIV-1-induced cell death proceeded unabated in the presence of these drugs. The viral infection process was not disrupted by piceatannol or indirubin, except at the higher concentration of piceatannol (30 M), since we found that the percentage of cells expressing the provirus was comparable between treated and untreated infected cultures (Fig. 6D, upper right panel) . Together, these data provide strong evidence that G 2 /M-phase arrest is not required for HIV-1 cytopathicity. Furthermore, the G 2 /M-independent death is not observed when Vif and Vpr are removed from the virus (NL4-3 f-r-; Fig. 6D ), indicating that this killing requires Vif, Vpr, or a combination of the two proteins.
Cytopathic effects of a G 2 /M arrest deficient HIV-1 strain at a high MOI. The observation that HIV-1-induced cell death occurs independently of G 2 /M blockade is at odds with the observation that a vif-vpr-derivative of NL4-3 e-n-GFP (NL4-3 e-n-GFPf-r-) lacking G 2 /M arrest activity is largely noncytopathic (55) . To test the possibility that increased proviral expression during a G 1 or G 2 /M cell cycle blockade is responsible for cell killing, we examined the cytopathicity of NL4-3 e-n-GFPf-r-in Jurkat cells at MOIs ranging up to 18 with elevated viral protein production. Infected cells remained predominantly in G 1 regardless of the MOI (Fig.  7A) , confirming the inability of vif-vpr-NL4-3 to arrest in G 2 /M. At MOIs of 1 to 1.5, cells supported viral infection with minimal effects on viability, even though the majority (60 to 75%) of the culture was actively expressing the provirus (Fig. 7B, top panels) . At greater MOIs, viability fell to 50 and 30% by day 5 postinfection for cultures infected at MOIs of 7 and 18, respectively (Fig. 7B, top left plot) . Although cell killing could not be attributed to G 2 /M arrest, cell proliferation kinetics indicated that normal cell expansion was impaired in cultures infected at the higher MOIs (Fig. 7B, bottom right plot) . Another viral protein, such as Tat, which can cause G 1 arrest (32), may be responsible for the residual cell cycle inhibition.
From these observations, we hypothesized that infected cell death occurs when a viral component, such as one of the remaining viral proteins (Gag, Pol, Tat, Rev, and Vpu) or nucleic acid, accumulates in nondividing cells to concentrations greater than that in cells permitted to divide. Similarly, cells infected at high MOIs with multiple copies of an integrated provirus would be more likely to contain high concentrations of viral components due to more viral gene expression. We tested this by flow cytometric detection of the GFP MFI to measure quantitative differences in relative protein expression at the single-cell level. The GFP MFI was notably enhanced with increasing MOIs throughout the course of the infection (Fig. 7B, bottom left plot) . Thus, elevated viral expression correlated with the MOI, as well as with decreased proliferation. To verify that the proliferation block and cell death caused by NL4-3 e-n-GFPf-r-infection at high MOIs was specific to HIV-1 infection and not an artifact of elevated GFP expression, accumulation of unintegrated proviral DNA, or VSV-G exposure, we tested a VSV-G-pseudotyped NL4-3-derived lentivirus, NL-EGFP, that lacks all HIV-1 genes (42). This virus, which encodes EGFP under the cytomegalovirus promoter, failed to have any deleterious effects on cell viability and division (Fig. 7C, left plots) , despite a threefold increase in the GFP MFI compared to NL4-3 e-n-GFPf-r--infected cells (Fig. 7C , right plot inset). Therefore, HIV-1 cytopathicity appears to be a direct result of elevated HIV-1 provirus expression in nondividing cells and can occur independently of Vpr expression and G 2 /M arrest under extreme infection conditions.
DISCUSSION

AIDS is due to the massive depletion of CD4
ϩ T cells that occurs during the acute and chronic stages of HIV-1 infection. Direct viral killing of infected CD4 ϩ T-lymphocytes likely plays a role in this process. Given the established involvement of Vpr in HIV-1 cytopathicity (31, 60), we investigated how Vpr mediates T-cell death. The recent NMR structure for Vpr revealed a series of exposed hydrophobic residues in the third alpha-helix that we envision could function as a protein-protein binding domain (43) . Characterization of Vpr mutants in this region has led us to conclude that residues I63, L67, I70, and I74 are important for cell cycle arrest, cytopathicity, nuclear localization, and self-association. In particular, replacement of I63, L67, and I74 with glutamic acid severely disrupted Vpr cell cycle blockade activity and cytopathicity. These substitutions did not lead to decreased protein stability or diminished virion packaging or delivery, indicating that they did not cause global Vpr dysfunction. However, impaired nuclear localization and self-association of the cell cycle active mutant, I70S, suggests that Vpr does not execute its G 2 /M block function from within the nucleus and that Vpr oligomerization is likely not necessary for cell cycle blockade. Regardless, our data represent the first confirmation that Vpr-Vpr binding occurs in live, unaltered human cells expressing endogenous Vpr. Vpr oligomerization may actually diminish G 2 /M arrest, however, or the arrest may involve a release from self-binding. Finally, G 2 /M arrest-impaired Vpr mutants were cytopathic when expressed in the context of an HIV-1 infection, which may be due to cell cycle dysfunction in the G 1 phase rather than in G 2 /M. HIV-1 toxicity independent of G 2 /M cell cycle blockade was also observed by chemical inhibition of the cell cycle in G 1 . Combined, these data suggest that an overall arrest of cell proliferation, and not accumulation in G 2 /M, is required for viral cytotoxicity.
Analysis of these mutants has also provided important insights into the significance of Vpr nuclear localization and self-association for cell cycle blockade activity. Neither of these properties was required for Vpr cell cycle arrest, since the active mutant, I70S, was expressed predominantly in the cytoplasm and did not oligomerize. Although the low-level nuclear expression observed for this mutant may be sufficient for cell cycle blockade, other cytoplasmic Vpr mutants, such as L68S, that retain G 2 /M block activity have been reported (14, 36) . Thus, our data are consistent with a model in which Vpr inhibits cell cycle progression from an extranuclear site, such as through interaction with the cytoplasmic scaffolding protein 14-3-3 (30) . Since the hydrophobic patch mutants were generally deficient in nuclear localization and self-binding, this region may mediate Vpr binding to nuclear transport factors (50, 67) or other Vpr molecules. Moreover, this correlation may indicate a role for Vpr self-association in nuclear import. Although NMR studies of Vpr C-terminal fragments implicated the neighboring hydrophobic residues-I61, L64, and L68-in mediating Vpr dimerization (6) , altered protein folding in the absence of the N terminus or the in vitro conditions used in these studies may account for this discrepancy. Interestingly, the enhanced self-association of mutants in the C-terminal In summary, Vpr oligomerization does not play a direct role in G 2 /M arrest induction but may serve to facilitate nuclear entry and is likely mediated by hydrophobic residues in the third alpha-helix. It is also possible that Vpr self-association negatively regulates the G 2 /M arrest activity, since many of the mutants showed an inverse relationship between self-binding and G 2 /M blockade. Although interpretation of these experiments is limited by their reliance on Vpr overexpression, Vpr is highly expressed in HIV-1-infected cells and thus may behave similarly under physiologic conditions. Our site-directed mutagenesis studies suggest that the third alpha-helix of Vpr mediates diverse Vpr functions. We speculate that this is most likely due to disruption of a crucial protein-protein interaction function served by the hydrophobic residues on the outer surface of this helix. Vpr is a 14-kDa protein without known enzymatic activity or domain motifs, so it seems likely that it works by binding other, presumably cellular, proteins. The unique ability of glutamic acid substitutions in this region to cripple Vpr activity, compared to alanine or serine, suggests that the negative charge or larger side chain is particularly damaging to Vpr function. It is also possible that the remaining unaltered hydrophobic residues in the alanine and serine substitution mutants may provide sufficient surface area for a protein partner to bind. One possibility is that the basic C-terminal domain is drawn in toward the negatively charged mutant third helix by electrostatic forces, competing for binding of a cellular partner to the hydrophobic patch. This could also prevent proper functioning or modification of the C terminus, which is known to be critical for Vpr cell cycle arrest activity (74) . It is also possible that this region is important for proper folding of Vpr, although the external orientation of the targeted residues may not affect intrinsic folding. Thus, we favor the conclusion that the third helix is directly responsible for Vpr functions, perhaps by associating with a cellular protein.
Our results uncovered a hitherto-unrecognized distinction between direct Vpr cytotoxicity and cell death mediated by HIV-1 infection. For death induced by Vpr alone (i.e., virionassociated Vpr), cell cycle blockade in G 2 /M was important. Cell death was proportional to the dose of Vpr v added to cells and invariably preceded by cell cycle blockade for at least 24 h (data not shown). In addition, Vpr point mutants attenuated in G 2 /M arrest activity showed a direct correlation between cell death and cell cycle blockade. This is consistent with previous correlations using other Vpr mutants (60, 71) and abrogation of Vpr-induced cell death by chemically blocking cells in G 1 (2) . It is important to note that these studies, like our Vpr v experiments, were conducted in systems in which Vpr was expressed in the absence of other viral proteins and bone fide HIV-1 infection. However, examples of Vpr mutants, such as I81P, which kill independent of cell cycle activity, are at odds with our findings (11, 47) . One possible explanation for this discrepancy is that, in the case of I81P, introduction of a proline in the middle of a potential fourth alpha-helix might significantly change the overall structure and function of the protein, in spite of the fact that the protein was intact (43, 47) . Other studies demonstrating independent G 2 /M arrest and cell death activity by Vpr were conducted in fission yeast (11) . Effects in this simple eukaryote may not recapitulate the interplay between cell cycle regulation and cell death in human cells. Thus, our data strengthen the argument for a correlative, and likely causal, relationship between G 2 /M cell cycle arrest and cell death.
In contrast to direct Vpr death induced upon virion delivery, HIV-1 cytopathicity can occur independently of G 2 /M cell cycle blockade. That is, although Vpr toxicity may rely on a G 2 /M block, death due to actual HIV-1 infection did not. Vpr mutants that cannot arrest in G 2 /M retained lethal properties when expressed in the context of viral infection but not during virion-mediated delivery. This appears to be due to a previously unknown ability of Vpr to cause cell cycle arrest in the G 1 phase, as well as in G 2 /M, in human T cells. It is not clear whether Vpr blockade in G 1 occurs in contexts other than during viral infection, although two lines of evidence suggest that this may be an inherent property of the protein: (i) cell cultures arrested by WT Vpr v contain a minor population (ϳ10%) of cells in G 1 with diploid DNA that fail to proliferate and (ii) Vpr arrests murine cells in G 1 (3, 46) . One explanation for this phenomenon is that Vpr G 1 arrest is most apparent in mammalian cells only if the G 2 /M blockade activity is attenuated. Given the emerging role of Cdk1 in regulating multiple phases of the mammalian cell cycle (37), it seems possible that Vpr could inactivate aspects of Cdk1 function besides entry into mitosis. Alternatively, the classical G 1 kinases, Cdk4 and Cdk6, which are essential for hematopoietic cell proliferation in mice (37) , could also be targeted by Vpr. This could lead to an arrest in G 1 even if the Cdk1 inactivating function of Vpr is not intact. Regardless of the mechanism, the cytopathicity of our Vpr mutant HIV-1 strains is consistent with ex vivo studies of human lymphoid tissue infected with R80A mutant CXCR4-tropic HIV-1 (51). Rajan et al. observed significant CD4 ϩ T-cell depletion using either the R80A mutant or the WT Vpr virus. In contrast, vpr-deleted HIV-1 was impaired for CD4 ϩ T-cell depletion. Although it has also been reported that in vitro T-cell infection with HIV-1 harboring non-G 2 /M-arrresting mutants such as R80A fail to cause cell killing (71) , these studies did not control for the level of infection at the singlecell level.
Why a failure of HIV-1-infected cells to proliferate leads to cell death remains unclear. Proviral proteins and nucleic acid may accumulate to higher concentrations in cells prevented from dividing and diluting their contents into daughter cells. Elevations of one or more viral components could ultimately be lethal. Increased viral protein expression in noncycling infected cells may also result from augmented transcription. Transcription from the HIV-1 promoter is upregulated specifically in G 2 /M, but a G 1 /S blockade also transactivates the long terminal repeat, albeit to a smaller extent (19) . Alternatively, protein translation or stability may be enhanced in nonproliferating cells. This model is supported by in vivo studies demonstrating a correlation between viral protein levels and cell death, since cells expressing HIV-1 mRNA at high levels have a shorter life span than those with less mRNA (9) . It is also a distinct possibility that conflicting cell cycle regulatory signals, such as from Vpr and Tat, which can arrest cells in the G 1 phase (32), may trigger cells to die through a process related to mitotic catastrophe (54) . In summary, blocking cell prolifera-tion, regardless of the cell cycle phase, increases the cytopathic nature of HIV-1 infection, although a specific death mechanism remains to be elucidated.
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